|Slideshows|June 12, 2021

Children’s Mental Health Response to COVID-19

What impact has the pandemic had on children's mental health?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

ByGustavo Alva, MD, DFAPA,Ann Childress, MD

June 26th 2026

What Should Psychiatrists Know About Pediatric Sleep Apnea and Insomnia Treatment?

ByCarol Rosen, MD

June 22nd 2026

No Screens Before Bed: Teen Smartphone Use at Bedtime Predicts Overnight Phone Activity

ByLeah Kuntz,Gina M. Mathew, PhD

June 15th 2026

“Engineered Addiction”: Redefining Addictive Disorders and the Psychiatric Impact of Social Media

ByLeah Kuntz

June 8th 2026

FDA Issues CRL for CTx-1301 for Treatment of ADHD

ByJessica Walters

June 2nd 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Children’s Mental Health Response to COVID-19

Related Content

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

What Should Psychiatrists Know About Pediatric Sleep Apnea and Insomnia Treatment?

No Screens Before Bed: Teen Smartphone Use at Bedtime Predicts Overnight Phone Activity

“Engineered Addiction”: Redefining Addictive Disorders and the Psychiatric Impact of Social Media

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Vol 43, Issue 7 - Interactive

Psychedelics, Orexin Blockers, and More: Inside the Diverse New Pipeline for Depression

Beyond Deprescribing: A Formula for Excellent Clinical Care

Long-Acting Injectables in Schizophrenia: Closing the Gap Between Evidence and Practice

VY1706 for Treatment of Alzheimer Disease Shows Tau Reductions and Favorable Tolerability